Public health concerns for anti-obesity medicines imported for personal use through the internet: A cross-sectional study

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Khan, Mohiuddin Hussain ^a   Tanimoto, Tsuyoshi ^b   Nakanishi, Yoko ^a,c   Yoshida, Naoko ^a   Tsuboi, Hirohito ^a   Kimura, Kazuko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^c Health Center of Kanazawa City   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; MEVINOLIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG APPROVAL; DRUG QUALITY; DRUG USE; HEALTH CARE DELIVERY; HEALTH CARE INDUSTRY; HEALTH SERVICE; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNET; JAPAN; MEDICAL LITERATURE; OBESITY; OUTCOME ASSESSMENT; PURCHASING; SAMPLE; TEA; WORLD HEALTH ORGANIZATION;

EID: 84863700755     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000854     Document Type: Article

References (62)

1. Madden M. America's Online Pursuits: the Changing Picture of Who's Online and What They Do. Washington, DC: Pew Internet, 2003.
2. Atkinson NL, Saperstein SL, Pleis J. Using the internet for health-related activities: findings from a national probability sample. J Med Internet Res 2009;11:e4.
3. Askola K, Atsushi T, Huotari ML. Cultural differences in the health information environments and practices between finnish and Japanese university students. Inform Res 2010;15:451.
4. Takahashi Y, Ohura T, Ishizaki T, et al. Internet use for health-related information via personal computers and cell phones in Japan: a cross-sectional population-based survey. J Med Internet Res 2011;13:e110.
5. Araki R, Okumura J, Akazawa M, et al. A survey on the awareness of consumers on their personal import of medicines from public health view point. Jpn J Soc Pharm 2010;28:134-5.
6. WHO. Medicines: Counterfeit Medicines. Geneva: World Health Organization, 2010; [Fact sheet No. 275]. http://www.who.int/mediacentre/factsheets/fs275/en/ index.html (accessed 8 Mar 2010).
7. WHO. Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs. Geneva, Switzerland: Department of Essential Drugs and Other Medicines, World Health Organization, 1999. Report No.: (WHO/EDM/QSM/99.1).
8. WHO. General Information on Counterfeit Medicines. Geneva: World Health Organization, 2009. http://www.who.int/medicines/services/counterfeit/overview/ en/ (accessed 27 May 2009).
9. IMPACT. Principles and Elements for National Legislation against Counterfeit Medical Products: Text Endorsed by IMPACT General Meeting. Lisbon: International Medical Products Anti-Counterfeiting Taskforce, 2007.
10. WHO. What Are Substandard Drugs? Geneva: World Health Organization, 2009. http://www.who.int/medicines/services/counterfeit/faqs/06/en/index.html (accessed 15 Jul 2009).
11. Surendran A. World agencies try to stem flood of fake drugs. Nat Med 2004;10:111. (Pubitemid 38524866)
12. Kelesidis T, Kelesidis I, Rafailidis PI, et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007;60:214-36. (Pubitemid 47248427)
13. Kaur H, Goodman C, Thompson E, et al. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 2008;3:e3403.
14. Onwujekwe O, Kaur H, Dike N, et al. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 2009;8:22.
15. Newton PN, Green MD, Fernández FM, et al. Counterfeit antiinfective drugs. Lancet Infect Dis 2006;6:602-13.
16. Khan AY, Ghilzai NM. Counterfeit and substandard quality of drugs: the need for an effective and stringent regulatory control in India and other developing countries. Indian J Pharmacol 2007;39:206-7.
17. Newton PN, Fernández FM, Plançon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008;5:e32.
18. Liang BA, Mackey T. Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. Am J Law Med 2009;35:125-84.
19. Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci 2011;100:4571-9.
20. Letkiewicz S, Górski A. The potential dual use of online pharmacies. Sci Eng Ethics 2010;16:59-75.
21. WHO. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Geneva: World Health Organization, 2008.
22. James WPT. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-52. (Pubitemid 351342683)
23. Moreno LA, Pigeot I, Ahrens W, et al. Prevalence of Overweight and Obesity in Japan. Epidemiology of Obesity in Children and Adolescents. New York: Springer, 2011:153-62.
24. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;142:525-31.
25. Lowes R, Waknine Y. FDA Announces Sibutramine Has Been Withdrawn From the Market. Medscape Education [serial on the Internet]. 2010. http://www.medscape. org/viewarticle/730515 (accessed 25 Oct 2011).
26. FDA. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). Rockville, MD, 2010. http://www.fda.gov/Drugs/ DrugSafety/ucm228746.htm (accessed 25 Oct 2011).
27. MHLW. Authorization Status of Drugs in Japan. Tokyo: Ministry of Health and Labour Welfare, 2011. http://www.info.pmda.go.jp/psearch/html/menu-tenpu- base.html (accessed 30 Jun 2011).
28. Tsuji K, Tsutani K. Personal imports of drugs to Japan in 2005 e an analysis of import certificates. J Clin Pharm Ther 2008;33:545-52.
29. Eisai. Withdrawal of Approval for Manufacture and Sale of A Therapeutic Agent for Obesity in Japan KES524. Tokyo: Eisai Co., Ltd., 2010. http://www.eisai.co.jp/news/news201057.html (accessed 7 Mar 2010).
30. deKieffer DE. The internet and the globalization of counterfeit drugs. J Pharm Pract 2006;19:171-7.
31. Jackson G. Faking it: the dangers of counterfeit medicine on the internet. Int J Clin Pract 2009;63:181.
32. Bogenschutz MP. Drugs on the internet. Am J Psychiatry 2001;158:2094-5.
33. MHLW. Warning on Health Hazard Due to Counterfeit Medicines. Tokyo: Ministry of Health and Labour Welfare, 2011. http://www.mhlw.go.jp/stf/houdou/ 2r9852000001agwf-att/2r9852000001ah0e.pdf (accessed 4 Oct 2011).
34. Pfizer. Result of Joint Investigation Done by Four Manufacturers: Approximately 60% of ED Treatment Medicines are Counterfeits on the Internet. Tokyo, 2009. http://www.pfizer.co.jp/pfizer/company/press/2009/2009-12-02.html
35. Kimura K, Honma T, Tanimoto T, et al. Public health implication of personal import of medicines through internet brokers (2): buying anti-obsity agents on-line. J Health Care & Society 2011; 21:55-67.
36. METI. Specified Commercial Transaction Law to Regulate Mail-order Business. Tokyo, Japan: Ministry of Economy, Trade and Industry, 1976.
37. Aka E, Legris C, Tanimoto T, et al. Counterfeit medicine detection by authenticity investigation: a pilot study in the street market of Côte d'Ivoire. Jpn J Soc Pharm 2005;24:7-16.
38. MHLW. Pharmaceutical Affairs Law, Japan. Tokyo: Ministry of Health and Labour Welfare, 2011. http://www.houko.com/00/01/S35/145.HTM (accessed 4 Oct 2011).
39. Nazeri A, Massumi A, Wilson JM, et al. Arrhythmogenicity of weightloss supplements marketed on the Internet. Heart Rhythm 2009;6:658-62.
40. Veronin MA, Youan BB. Magic bullet gone astray: medications and the internet. Science 2004;305:481. (Pubitemid 38971327)
41. Martin-Facklam M, Kostrzewa M, Schubert F, et al. Quality markers of drug information on the internet: an evaluation of sites about St. John's Wort. Am J Med 2002;113:740-5. (Pubitemid 36044700)
42. Westenberger BJ, Ellison CD, Fussner AS, et al. Quality assessment of internet pharmaceutical products using traditional and nontraditional analytical techniques. Int J Pharm 2005;306:56-70. (Pubitemid 41643140)
43. Orizio G, Rubinelli S, Schulz PJ, et al. "Save 30% if you buy today". Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol Drug Saf 2010;19:970-6.
44. Orizio G, Merla A, Schulz PJ, et al. Quality of online pharmacies and websites selling prescription drugs: a systematic review. J Med Internet Res 2011;13:e74.
45. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009;5:441-52.
46. EMEA. European Medicines Agency Recommends Suspension of Marketing Authorisation for Sibutramine. London: European Medicines Agency, 2010. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2010/01/ news-detail-000985.jsp&murl=menus/news-and-events/news-and-events. jsp&mid=WC0b01ac058004d5c1 (accessed 9 Jun 2011).
47. EMEA. European Medicines Agency Recommends First Switch From Prescription Only to Non-Prescription for a Centrally Authorised Medicine. 2008. Doc. Ref. EMEA/CHMP/493770/2008. http://www.ema. europa.eu/ema/index.jsp?curl=pages/news- and-events/news/2009/11/news-detail-000256.jsp&murl=menus/news-and-events/ news-and-events.jsp&mid=C0b01ac058004d5c1&jsenabled=true (accessed 24 Jun 2011).
48. Weidmann A, Cunningham S, Gray G, et al. Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain. Int J Clin Pharm 2011;33:1-7.
49. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007;99:379-81. (Pubitemid 46157217)
50. Calza L. Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. Drug Healthc Patient Saf 2009;1:25-33.
51. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007;15:2712-22.
52. EMEA. European Medicines Agency Recommends Withdrawal of Benfluorex from the Market in European Union. London: European Medicines Agency, 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2010/01/ news-detail-000977.jsp&murl=menus/news-and-events/news-and-events. jsp&mid=WC0b01ac058004d5c1&jsenabled=true (accessed 9 Jun 2011).
53. EMEA. Public Statement on Acomplia: Withdrawal of the Marketing Authorisation in the European Union. London: European Medicines Agency, 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2009/11/ news-detail-000126. jsp&murl=menus/news-and-events/news-and-events. jsp&mid=WC0b01ac058004d5c1 (accessed 9 Jun 2011).
54. Khan M, Okumura J, Sovannarith T, et al. Counterfeit medicines in CambodiadPossible Causes. Pharm Res 2011;28:484-9.
55. FDA Warns Consumers about Counterfeit Alli [database on the Internet]. U.S. Food and Drug Administration, 2010. http://www.fda. gov/NewsEvents/ Newsroom/PressAnnouncements/ucm197857.htm (accessed 3 Oct 2011).
56. UPDATED Public Health Alert: Counterfeit Alli Containing Sibutramine [database on the Internet]. U.S. Food and Drug Administration, 2010. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm198519.htm (accessed 3 Oct 2011).
57. Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004;9:1241-6. (Pubitemid 40037159)
58. Khan MH, Okumura J, Sovannarith T, et al. Prevalence of counterfeit anti-helminthic medicines: a cross-sectional survey in Cambodia. Trop Med Int Health 2010;15:639-44.
59. Lineberry TW, Bostwick JM. Taking the physician out of "physician shopping": a case series of clinical problems associated with internet purchases of medication. Mayo Clin Proc 2004;79:1031-4. (Pubitemid 39007024)
60. MHLW. Pharmaceutical Affairs Law, Japan. Tokyo: Ministry of Health and Labour Welfare, 1961. http://www.houko.com/00/01/S35/145. HTM (accessed 4 Oct 2011).
61. Mackey TK, Liang BA. Promoting online drug safety: using public-private partnerships to deter illicit online drug sales. J Commer Biotechnol 2011;17:266-71.
62. Cockburn R, Newton PN, Agyarko EK, et al. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2005;2:e100.